share_log

外资药企绣球抛给中国创新药企 竞争格局或生变

Foreign pharmaceutical companies throw hydrangeas to China's innovative pharmaceutical companies, the competitive landscape may change

Moomoo 24/7 ·  Jan 9 13:30
Recently, frequent mergers and acquisitions by multinational pharmaceutical companies have attracted market attention. From December 26, 2023 to January 9, 2024, in just 15 days, there have been at least 4 mergers and acquisitions in the global pharmaceutical market, involving leading global pharmaceutical companies such as AstraZeneca, Novartis, MSD, and Johnson & Johnson. It is worth noting that innovative pharmaceutical companies in China have appeared on mergers and acquisitions several times. Industry insiders generally believe that this shows that the R&D strength of local Chinese pharmaceutical companies has been recognized internationally. At the same time, it may also change the competitive landscape of the local pharmaceutical market. “Foreign pharmaceutical companies may acquire innovative local pharmaceutical companies, or accelerate the transformation process of innovative local pharmaceutical companies, so that they can improve their R&D strength and market competitiveness faster, and make some large local pharmaceutical companies face greater competitive pressure.” Yu Xiaoming, senior investment advisor at Jufeng Investment, told reporters. (Securities Daily)
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment